Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

G1 Therapeutics Inc (NQ: GTHX )

7.150 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about G1 Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
- Jupiter Bioventures will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib for Radioprotection in the US, Europe, Japan, and All Other... 
From G1 Therapeutics
Via GlobeNewswire
Evaluating G1 Therapeutics: Insights From 5 Financial Analysts
Via Benzinga
What's Going On With G1 Therapeutics Stock?
According to a report, G1 Therapeutics has received and rejected multiple offers from TerSera Therapeutics. According to the report, one offer from TerSera is rumored to have a contingent value right... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
GTHX Stock Earnings: G1 Therapeutics Beats EPS, Misses Revenue for Q1 2024
GTHX stock results show that G1 Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
- Pepper Bio will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib in the US, Europe, Japan, and All Other Global Markets Excluding... 
From G1 Therapeutics
Via GlobeNewswire
Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
Via Benzinga
Biotech Innovations Paving the Way in Breast Cancer Fight
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:GTHX),(NASDAQ:AZN),(NASDAQ:HOLX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Forecasting The Future: 5 Analyst Projections For G1 Therapeutics
Via Benzinga
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Why Is Breast Cancer-Focused G1 Therapeutics Stock Trading Lower Today?
Follow G1 Therapeutics as it advances trilaciclib in Phase 3 PRESERVE 2 trial for metastatic triple-negative breast cancer. Updates on trial progress, interim analysis, and potential FDA filing in... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Evercore ISI Is Warming Up to NextEra Energy (NEE) Stock
NextEra Energy stock is on the move Tuesday after Evercore ISI initiated coverage of NEE shares with a bull rating and price target. 
Via InvestorPlace
UBS Just Upped Its Nvidia (NVDA) Stock Price Target
Nvidia stock is a hot topic among NVDA traders on Tuesday after the company's shares got a new $850 price target from UBS analysts. 
Via InvestorPlace
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance. 
Via Benzinga
Why ZoomInfo Technologies Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Shares of ZoomInfo Technologies Inc. (NASDAQ: ZI) rose sharply in today’s pre-market trading as the company reported stronger-than-expected fourth-quarter financial results. 
Via Benzinga
Why Is Polished.com (POL) Stock Down 33% Today?
Polished.com stock is sliding lower on Tuesday as investors in POL react to the company missing a debt payment and other dangers. 
Via InvestorPlace
Why Is G1 Therapeutics (GTHX) Stock Down 45% Today?
G1 Therapeutics stock is down on Tuesday after the company provided GTHX investors with an update on a Phase 3 clinical trial. 
Via InvestorPlace
ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a hot topic on Tuesday and we're diving into all of the biggest winners and losers this morning! 
Via InvestorPlace
Arista Networks Reports Q4 Results, Joins Teradata, Lattice Semiconductor And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq futures trading lower by around 100 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
From G1 Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.